Table 3.

Studies of FIGO stage and prognosis of human papillomavirus (HPV)-negative cervical cancers.

Study (Reference)	Cases (HPV negative/overall)	HPV testing	Advanced FIGO stage (HPV negative vs. HPV positive)	Lymphatic metastasis (HPV negative vs. HPV positive)	DFS (HPV negative vs. HPV positive)	OS (HPV negative vs. HPV positive)
Nicolas et al. (57)	21/214	PCR	91% vs. 57%, p<0.01	67% vs. 36%, p<0.01	59.8 m (95%CI 32.0–87.6 m) vs. 132.2 m (95%CI 118.6–145.8 m), p<0.01	77.0 m (95%CI 47.2–106.8 m) vs. 153.8 m (95%CI 142.0–165.6 m), p=0.01
Van der Marel et al. (58)	8/136	HC2™, PCR L1&E7	87.5% vs. 52.3%, p=0.053	37.5% vs. 17.2%, p=0.150	51.9 m (95%CI 12.2–91.7 m) vs. 109.9 m (95%CI 98.2–121.5 m), p=0.010	67.7 m (95%CI 20.0–106.9 m) vs. 108.9 m (95%CI 97.7–120.0 m), p=0.225
Feng et al. (59)	43/122	PCR (HPV 16/18)	—	—	—	5 year: HR=1.250 (95%CI 0.562–2.784), p=0.584 8 year: HR=1.530 (95%CI 0.697–3.362), p=0.289

PCR, polymerase chain reaction; HC2, Hybrid Capture 2; DFS, disease-free survival; OS, overall survival; m, months; HR, hazard ratio; 95%CI, 95% confidence interval.